Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?

\\"Markets have already pulled forward a tremendous amount of good news,\\" says Lori Calvasina, head of US equity strategy at RBC Capital Markets, as she examines concerns expressed by companies so far this earnings season.

Scroll to Top